science wire

« BACK

Pharmacology



Results 601 - 650 of 1511.
« Previous 1 ... 9 10 11 12 13 14 15 16 17 ... 31 Next »


Health - Pharmacology - 10.11.2017
Use of antibiotics - only if necessary
Bern, 10.11.2017 - Spearheading the fight against antimicrobial resistance, the World Health Organization (WHO) launched its Antibiotic Awareness Week.

Pharmacology - Health - 10.11.2017
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept   Significantly fewer brolucizumab patients showed signs o

Health - Pharmacology - 08.11.2017
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer MONALEESA-7 met primary e

Health - Pharmacology - 07.11.2017
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation.

Pharmacology - Health - 07.11.2017
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage Structural joint damage in psoriatic art

Health - Pharmacology - 06.11.2017
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL Applica

Health - Pharmacology - 06.11.2017
Novartis seeks leadership with Cosentyx showing no radiographic progression in ankylosing spondylitis at 4 years
For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx have no radiographic progression of the spine at 4 years These new data also confirm sustained improvement in signs and symptoms in almost 80 percent of patients, with a favorable and consistent safety profile Cosentyx, the only IL-17A inhibitor approved for AS, is a fully human, highly targeted biologic for first-line use in this

Health - Pharmacology - 02.11.2017
Disabled people set to guide fitness industry in new research project
A University of Birmingham academic has led the authorship of the UK's first guideline on the care of adults with systemic lupus erythematosus (lupus). Published today in Rheumatology, the guideline has been created by the British Society of Rheumatology, and covers diagnosis, assessment, monitoring and treatment of patients with mild, moderate and severe lupus.

Pharmacology - Life Sciences - 02.11.2017
Novartis and Amgen announce expanded collaboration with Banner Alzheimer’s Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD)   Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD   Generation Study 2 aims to include a broader high-risk population, as compared to the ongoing Generation Study 1        44 million people globally are e

Pharmacology - Health - 01.11.2017
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia

Pharmacology - Health - 01.11.2017
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal Kymriah TM Phase II JULIET study in relapsed/refractory DLBCL † Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickl

Health - Pharmacology - 31.10.2017
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy Submission based on updated

Pharmacology - Health - 30.10.2017
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation † Acquisition would add Lutathera , a first-in-class RadioLigand Therapy (RLT) app

Health - Pharmacology - 30.10.2017
Novartis to present first of its kind evidence for Cosentyx on potential to maintain mobility in patients with AS and PsA
Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting , † Structural disease progression is a major c

Pharmacology - Health - 28.10.2017
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs.

Pharmacology - Health - 27.10.2017
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of oncology

Pharmacology - 25.10.2017
Statins are not always prescribed to the patients who will benefit most
New research reveals eight in ten nurses face barriers to working in a caring and compassionate manner. Staff reductions, time pressures and “pen-pushing” are leading to moral disengagement - and compromising professional practice, according to new research published today by the University of Birmingham.

Pharmacology - Health - 25.10.2017
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
Full data from the pivotal Phase III PARADIGMS study of Gilenya (fingolimod) in pediatric MS will be presented for the first time † With 54 accepted abstracts, Novartis presence spans from new siponimod (BAF312) data in secondary progressive MS (SPMS) to innovative research on neurofilaments - a promising MS biomarker - Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at

Pharmacology - Business / Economics - 24.10.2017
Novartis delivered growth on top and bottom line in all divisions in Q3
Net sales grew 2% (cc , +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew driven by imp

Health - Pharmacology - 23.10.2017
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients Breakthrough Therapy Designation ba

Health - Pharmacology - 18.10.2017
’Role Model’ teachers found to be central to good character education
GPs can be reluctant to refer patients with symptoms of bowel cancer for further investigations, a study by the Universities of Birmingham and Exeter has found.

Health - Pharmacology - 18.10.2017
Novartis drug Revolade shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Nearly 70% of patients maintained platelet counts of >=30◊10 9 /L without rescue therapy for prolonged periods, reducing the overall risk of bleeding † More than one-third of patients permanently

Health - Pharmacology - 16.10.2017
Endogenous Infection Marker Guides Antibiotic Therapy
The endogenous infection marker procalcitonin can help to guide the use of antibiotics when treating infections.

Pharmacology - Health - 28.09.2017
Novartis and UC Berkeley collaborate to tackle ’undruggable’ disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer   New Novartis-Berkeley Center for Proteomics and Ch

Health - Pharmacology - 26.09.2017

Pharmacology - Health - 26.09.2017
Even Open-Label Placebos Work - if They Are Explained
Even Open-Label Placebos Work - if They Are Explained
For some medical complaints, open-label placebos work just as well as deceptive ones. As psychologists from the University of Basel and Harvard Medical School report in the journal Pain, the accompanying rationale plays an important role when administering a placebo. The successful treatment of certain physical and psychological complaints can be explained to a significant extent by the placebo effect.

Pharmacology - Health - 22.09.2017
Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people wit

Pharmacology - Health - 22.09.2017
Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche receives European approval for Actemra /RoActemra in giant cell arteritis Actemra/RoActemra is the first therapy approved for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The approval was based on the outcome of the phase III GiACTA study Roche announced today that the European Commission (EC) has approved Actemra /RoActemra (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition.

Pharmacology - Health - 22.09.2017
Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma
Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche announced today that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment for previously untreated advanced follicular lymphoma.

Health - Pharmacology - 22.09.2017
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model † GIPAP was introduced 15 years ago and has provi

Health - Pharmacology - 20.09.2017
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Significant overall surviv

Pharmacology - Health - 18.09.2017
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche announced today that the phase III MURANO study, which evaluated Venclexta /Venclyxto (venetocla

Pharmacology - Health - 16.09.2017
Novartis’ Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled † Should a treatment pause be necessary, data showed almost 90% of chronic spontaneous urticaria (CSU) patients - previously well controlled - regained effective symptom control within 12 weeks of re-treatment on Xolair † Previous studies have shown that inadequately controlled CSU has a major impact on sleep, social l

Health - Pharmacology - 15.09.2017
New Study on the Placebo Effect and Antidepressants in Children and Adolescents
New Study on the Placebo Effect and Antidepressants in Children and Adolescents
Although the clinical efficacy of antidepressants in children and adolescents is proven, it is frequently accompanied by side effects. In addition, the influence of the placebo effect on the efficacy of antidepressants is unclear. A meta-analysis of data from over 6,500 patients has now shown that, although antidepressants are more effective than placebos, the difference is minor and varies according to the type of mental disorder.

Health - Pharmacology - 14.09.2017
Parasitic Worms in Siberia
Parasitic Worms in Siberia
Millions of people worldwide are infected with parasitic worms, most of them in tropical low-income settings.

Health - Pharmacology - 14.09.2017
Increase of antibiotic resistance - Antibiotic Awareness Week highlights the risks
Bern, 14.09.2017 - The global fight against antibiotic resistance is ramping up. The World Health Organization has launched an Antibiotic Awareness Week, which will be running for the first time in Switzerland from 13 to 19 November 2017.

Pharmacology - Health - 14.09.2017
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases Holzkirchen, Septem

Health - Pharmacology - 13.09.2017
Vessels that help cancers spread can also boost cancer immunotherapy
Vessels that help cancers spread can also boost cancer immunotherapy
Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. Many cancers, such as melanoma, are known to metastasize and spread by expanding nearby lymphatic vessels. This process, lymphangiogenesis, also helps the tumor evade the patient's own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of patients.

Pharmacology - Health - 13.09.2017
Novartis’ Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Cosentyx (secukinumab) is the first and only fully human IL-17A † inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis † Landmark data show that PASI 90 and PASI 100

Pharmacology - Health - 12.09.2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our

Pharmacology - Health - 11.09.2017
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma.

Health - Pharmacology - 11.09.2017
Adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
Novartis Phase III study demonstrates adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma The three-year relapse

Health - Pharmacology - 09.09.2017
Novartis presents new data at EURETINA 2017 confirming Lucentis efficacy and durability vs aflibercept
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD † Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17 th EURETINA Congress in Barcelona, Spain (September 7-10, 2017).

Health - Pharmacology - 08.09.2017
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment Safety profile was in line with previous lampalizumab trials and other intravitreal therapies Results from the second phase III study, Chro

Pharmacology - Health - 08.09.2017
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September 2017 in Madrid, Spain.

Pharmacology - Health - 07.09.2017
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need   Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consisten

Pharmacology - Health - 06.09.2017
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche today announced results from the global phase III ALUR study showing that Alecensa significantly reduc
« Previous 1 ... 9 10 11 12 13 14 15 16 17 ... 31 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |